Medicines Transparency Alliance08/08/2015 1 MeTA Peru Country Overview Public Sector Private Sector...

Medicines Transparency Alliance19/04/23 1

MeTA Peru

Country OverviewPublic SectorPrivate SectorCivil Society


MeTA Peru

Germán Rojas, Technical SecretaryLeda M. Perez, Consultant to MeTA in Peru


Multi-stakeholder process

A commitment to engage– Received a commitment from the MoH in early 2008 to participate in MeTA– Participation of public and private sectors and civil society in MeTA global

launch of May, 2008

A commitment to proceed– Birth of the Grupo Impulsor, June 2008– MeTA Peru National Forum, November, 2008– Consolidation of Executive Committee and National Council between

November, 2008 and February, 2009– Refinement of MeTA Peru national work plan, February, 2009-February, 2010

A commitment to implement– Executive Committee continues to meet weekly to make decisions relative to

work plan implementation– National Council meets every two months to assess progress on work plan

Medicines Transparency Alliance

Major achievements and successes

All sectors remain at the table!– Continuous nature of multi stakeholder process– Communication has changed as a result of MeTA

Progress on key areas of implementation– Price Observatory– Public purchases study– Development of Centers for Medicines Information

Agreement on key areas to be implemented– Development of a national generics policy– Development of baseline data studies, i.e., pharmaceutical sector scan and

multi stakeholder process evaluation– Development of software for price observatory– Development of Website/communications plan

19/04/23 4


Overall challenges

The multi stakeholder process takes time– Sectors are working together which may have never had a history of

collaboration– Without trust and relationships it is impossible to move the agenda forward.– Must adapt to new structures, i.e., Executive Committee, National Council,

administrative and technical secretariats

The Executive Committee and National Council lead this process and not the Technical or Administrative Secretariats– This means that there are many minds at work and the Technical and

Administrative Secretariats are beholden to the will of these voluntary bodies and not the other way around

19/04/23 5


Lessons Learned

The multi stakeholder process may be a useful manner of creating transparency and improving decision-making in the pharmaceutical sector. However,– Investments in relationship- and trust-building are essential– Such a process is difficult anywhere in the world, but may be particularly

challenging in environments whose governments have been historically centralized.

While transparency in information about medicines and process is important, we must be careful that the mechanisms put in place do not create greater bureaucracies

There is value in a shared space between civil society, government and private sector to discuss common issues of concern.

19/04/23 6


Lessons Learned

19/04/23 7

PUBLIC SECTOR

CIVILSOCIETIES

PRIVATESECTOR

• MINSA• EsSalud• Defensoría del Pueblo• Facultad de Medicina de la UNMSM • Gobiernos Regionales: Arequipa, Huánuco, Piura

• Asociación Nacional de Laboratorios Farmacéuticos– ALAFARPE• Asociación Nacional de Industrias Farmacéuticas – ADIFAN• Comisión de Salud de Cámara de Comercio de Lima (COMSALUD)• Asociación Peruana de Entidades Prestadoras de Salud (APEPS)

• Colegio Médico del Perú • Acción Internacional para la Salud • Foro Salud • Red Peruana de Pacientes y Usuarios


Lessons Learned

19/04/23 8

PresidentVice-President15 Members

MoHOmbudsmanHAIMedical College of PeruALAFARPE

National Council MeTA Peru

Executive Committee MeTA Peru

Technical Secretariat

Communicator

AdministrativeSecretariat

Support: International consultant


Thank you

German Rojas, Technical Secretary

Leda M. Perez, Consultant to MeTA in Peru

Email: [email protected] and [email protected]

Mobile number: 511 99566 5509 (Leda) 511 999378102 (Germán)

Skype: leda568 and grojas3000

Website: www.metaperu.org


Peru – Public Sector

Melitón ArcePedro YarascaPedro Tintaya


Analytical Summary at the beginning of MeTA

What were the needs and problems in this specific sector at the beginning of MeTAProblems:

– Lax legislation for the Registration and Quality of medicines. – Little transparency in the information of prices.– Promotion and Publicity of medicines

Needs:

– Transparency in information of prices of Pharmaceutical Products

– Politics of Generic Medicines– Rational use of medicines: Listing of Essential Medicines of

the Health Sector– Greater availability and affordability of medicines


Registered medicines in Peru

Total of Medicines with Sanitary Registration in force: 23,022Fuente: SI-DIGEMID. Abril 2010

Nacional47%

Extranjero53%

Medicamentos de Marca

53%

Otros24%

Medicamento Generico

21%

Producto de origen

Biologico2%


Main mailstones

What milestones have been reached during the MeTA pilot phase?

During the period of the MeTA pilot phase, the following milestones have been achieved, favored by MeTA Peru:

Observatoriy of Prices of Pharmaceutical Products:– Regulatory framework for the OPPF– Development of the software for prices reports– Technological support :PCs, Server– Informative campaigns for the dissemination of the OPPF: Informative Modules

Aspects that have facilitated to reach this milestones: – New legislation of Pharmaceutical Products, medical devices and sanitary

products. – Obligatory nature of prescription in International Common Denomination (DCI)

19/04/23 13


Successes

What were the successes of the sector during the MeTA pilot phase?

– Elaboration and approval of the normative framework on the Observatory of Prices

– Launch of the Observatory of Prices - Currently in Version 2.

– Political commitment and support by the Minister of Health

– Acceptability of the Observatory of Prices by part of the population

19/04/23 14


Examples

Informative campaign on Prices of Medicines


Challenges

What challenges have this sector to confront during the MeTA Pilot Phase?

– To build a better trust among the associates.

– The presence of divergent opinions during the process.

– Greater capacity in technological and human resources.

19/04/23 16


Lessons Learned

What lessons has this sector learned of MeTA?

– Recognition of issues that should be revealed to the population (prices, availability, public purchases, information of medicines).

– Allowing space for multisectorial dialogue.

– Identification of objectives and common strategies among the associates, always respecting their points of view.

– It has permitted to identify prominent tissues for the country in matter

of medicines.

19/04/23 17


Thank you

Pedro Yarasca

e-mail: [email protected]

Telf.: 0051-1-998704127

www.digemid.minsa.gob.pe


Private Sector

Berenice PintoAugusto Rey



What were the needs and problems in this specific sector at the beginning of MeTA

• Quality

• Ilegal Market

• Ethics

• Regulation


Main mailstones


– Forming part of a roundtable where we are able to work together as a country on common interest (public, private and civil company).

– Communication among the private sector, the public sector and the civil company has improved.

– Communication of the companies that conform the private sector has improved (ADIFAN, ALAFARPE, COMSALUD-CCL).

– Joint appreciations as private sector on problems that normally require a major approach by the public sector.

19/04/23 21


SuccessesWhat were the successes of the sector during the MeTA pilot phase?

– Diffusion within the private sector of MeTA's objectives – Achieving commitment of the private sector stakeholders

on access to medicines. – Permanent participation in MeTA Peru of 3 of the 4 private

sector stakeholders. – Commitment and participation of ALAFAL– Better communication both inter and intra-sectorial. – Greater understanding of the multi-stakeholder process.

19/04/23 22


Challenges

What challenges has this sector confronted during the MeTA Pilot Phase?

– Sharing the concerns of the pharmaceutical sector.

– Contribute to a common agenda among private sector which is presented in MeTA Peru.

– Debate different points of view with other sectors .

19/04/23 23


Lessons Learned

What lessons has this sector learned of MeTA?

– Opportunity of dialogue among sectors. – The multi-stakeholder process allows to identify

common problems. – Engage the opportunity that the government of

the United Kingdom has offered us, to discuss pharmaceutical issues with transparency.

– It is possible to build a shared vision across sectors.

– Building trust is necessary among the sectors

19/04/23 24


Thank you

Berenice Pinto

C-electrónico: [email protected]

Número Celular: 511 992776311 / 511 4226480

Página Web: www.adifan.com.pe

Augusto Rey


Número Celular: 511 995491392 / 511 4410693

Página Web: www.alafarpe.com


Civil Society

Marco Alegre Romero – Coordination CSOs



What were the needs and problems in this specific sector at the beginning of MeTA?

43% of the country's population lacks access to essential medicines.

CSOs had not fluent access to essential critical information by the state and the private sector in relation to access to medicines.

There was limited space for Civil Society participation to generate public policy on essential medicines.

Absence of a National Policy for Generic Medicines.

Weakness in the mechanisms of transparency and accountability of public administration in the early stages of the medicines supply chain.


Main mailstones


Being able to start working together to address access to generic medicines, between the State, Civil Society and Private.

Forming a Coalition of Civil Society Organizations

To be able to formulate a national project by the CSOs Coalition and users, to train leaders in monitoring access to medicines.

19/04/23 28


Successes

Which were the successes of the sector during the MeTA pilot phase?

Raise the issue about lack of access to medicines at national and regional levels.

Reach an agreement with the University for the development of post-graduate courses to train leaders in monitoring access to medicines.

Manage to jointly formulate a project that contribute to access of medicines among the national and regional CSOs

The engagement of 18 out of 25 regions of the country in the implementation of the project

19/04/23 29


Challenges

What challenges has this sector confronted during the MeTA Pilot Phase?

To provide a better positioning of the CSOs on the National Council and the Executive Board of META Peru.

To achieve a cohesion between CSOs – Users, and technical people.

To engage active leaders in monitoring access to medicines at the national level articulated in the network.

19/04/23 30


Lessons Learned

What lessons has this sector learned from MeTA? You can better address the problem of access to essential medicines when working in collaboration with the state, civil society and the private sector.

The Civil Society can improve the quality of dialogue and negotiation with the public and private sector when it has continuous access to information.

The Civil society is divided according to the interests of each of its members.

The regions of Peru would like to address the problems ofaccess to essential medicines but do not have strategies and information to give an appropriate response.

19/04/23 31


Thank you

Marco Alegre Romero


Número Celular: (51) 1997273931

Skype:

Página Web: www.forosalud.org.pe

Medicines Transparency Alliance08/08/2015 1 MeTA Peru Country Overview Public Sector Private Sector...

Documents

Transcript of Medicines Transparency Alliance08/08/2015 1 MeTA Peru Country Overview Public Sector Private Sector...